Inmune Bio Inc. (INMB)

NASDAQ: INMB · Delayed Price · USD
6.81
0.48 (7.58%)
At close: May 27, 2022 3:26 PM
6.80
-0.01 (-0.15%)
After-hours:May 27, 2022 4:00 PM EDT
Market Cap122.21M
Revenue (ttm)340,000
Net Income (ttm)-32.69M
Shares Out17.95M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume164,560
Open6.43
Previous Close6.33
Day's Range6.33 - 7.00
52-Week Range4.63 - 30.37
Beta2.44
AnalystsBuy
Price Target22.78 (+234.5%)
Earnings DateMay 5, 2022

About INMB

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; a...

IndustryBiotechnology
IPO DateFeb 4, 2019
Employees10
Stock ExchangeNASDAQ
Ticker SymbolINMB
Full Company Profile

Financial Performance

In 2021, Inmune Bio's revenue was $181,000, an increase of 1,545.45% compared to the previous year's $11,000. Losses were -$30.34 million, 150.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for INMB stock is "Buy." The 12-month stock price forecast is 22.78, which is an increase of 234.51% from the latest price.

Price Target
$22.78
(234.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study

The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.

2 days ago - Zacks Investment Research

INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade

Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug...

3 days ago - Market Watch

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in A...

BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate...

4 days ago - GlobeNewsWire

INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th

Boca Raton, FL, May 18, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease...

1 week ago - GlobeNewsWire

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference o...

XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris

2 weeks ago - GlobeNewsWire

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

Company Dosed First Phase 2 Mild Alzheimer's Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies

3 weeks ago - GlobeNewsWire

INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day

4 weeks ago - GlobeNewsWire

INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disea...

1 month ago - GlobeNewsWire

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

1 month ago - Zacks Investment Research

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of A...

INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate...

1 month ago - GlobeNewsWire

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual M...

Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, and...

1 month ago - GlobeNewsWire

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival

1 month ago - GlobeNewsWire

INmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innat...

The Company also Plans on Sharing INKmune™ Patient Case Studies The Company also Plans on Sharing INKmune™ Patient Case Studies

1 month ago - GlobeNewsWire

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise of Xpro™ for Treatment International Conference on Alzheim...

2 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parki...

Conference Provides First Exposure of EU and UK AD Experts to INmune Bio's Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer's Disease

2 months ago - GlobeNewsWire

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual...

Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disea...

2 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update

Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in patient with high-risk myelodysplastic syndrome Opens Phase 2 mild Alzheimer's trial and reports po...

2 months ago - GlobeNewsWire

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

Management to host conference call and webcast at 4:30 pm ET on that day

3 months ago - GlobeNewsWire

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference

BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...

3 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopha...

Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune  Bio, Inc.  (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

4 months ago - GlobeNewsWire

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting

Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune  Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...

4 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast...

Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME

5 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day ...

Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's in...

5 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer's disease (AD)

6 months ago - GlobeNewsWire

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease ...

Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...

7 months ago - GlobeNewsWire